EPITOPE PREDICTION AS THERAPEUTIC VACCINE FOR POLIO

Abstract

The vaccines of polio are being used to halt poliomyelitis. They are of two types: inactivated poliovirus which is taken by injection and weakened poliovirus which is taken by mouth. To study the mechanism of the reversion of genes in live poliovirus in humans, the study of molecular evolution has to be done. The results came out from the recent vaccine try out that the rates of the substitution for the VP1 are higher for the isolates of sabin which is compared with the wild type. In polio transmission patterns geographical variation is important. Major Histocompatibility Complex class I binding prediction tool and CD8+ immunogenicity prediction tool are being used for the prediction of class I epitopes. Major Histocompatibility Complex class II binding prediction tool and CD4+ immunogenicity prediction tool are being used for the prediction of class II epitopes. Population coverage of the epitopes of MHC I and MHC II binding peptide was preconcieved in Indian population. Many population coverage epitopes were selected for each serotype. Epitopes were selected for VP1, VP2, VP3, VP4. A combinatorial epitope prediction would be used as a therapeutic vaccine for polio.